Ambrx to cut workforce, pause internal development of lead cancer drug candidate

Oct. 18, 2022 4:40 PM ETAmbrx Biopharma Inc. (AMAM)By: Anuron Mitra, SA News Editor
  • Ambrx Biopharma (NYSE:AMAM) on Tuesday said it would reduce its workforce by about 15%, pause the internal development of its lead drug candidate and now focus on its earlier stage cancer therapies as part of a strategic reprioritization of

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.